BOSTON PROBES GETS PATENT FOR PNA PROBE TECHNOLOGY.
The broadly claimed methods result in a substantial reduction in the non-specific signal in the assay as compared with conventional nucleic acid probe based hybridization assays to thereby improve the performance of the probe based assays far beyond that obtainable by mere optimization of stringency conditions. Such PNA probe based methods are particularly useful for any type of single nucleotide polymorphism (SNP) analysis. Thus, the patented methods can be applied to the development and commercialization of products in several areas including: basic research, genomics, forensic analysis, pharmaceutical discovery as well as food and environmental testing.
"The issuance of this patent is a major milestone in the history of our company," said Jack T. Johansen, Ph.D., president and CEO of Boston Probes. "We believe our innovative PNA technology, supported by key patents like this one, will accelerate the development of applications for PNA probes and foster the acceptance of PNA as a superior probe technology."
Boston Probes is a development stage company located in Bedford, Massachusetts. Boston Probes has, since 1996, been developing PNA probe technologies for use in agriculture, human and veterinary diagnostics as well as the detection of microorganisms in foods, beverages, water, the environment and other industrial processes such as pharmaceutical manufacturing.
In addition to the sale of its own products, Boston Probes is forming strategic partnerships that will allow its partners to quickly exploit the advantages of PNA technology within their products and thereby achieve a substantial competitive advantage in their respective strategic markets. The company commands an extensive PNA related intellectual property portfolio as derived from its own innovations as well as the in-licensing of PNA related inventions from DAKO A/S, PNA Diagnostics A/S and the Applied Biosystems Group of PE Corporation.
For more information, call 781/271-1100 x222.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 1, 2000|
|Previous Article:||COPERNICUS GETS PHASE I SBIR GRANT FOR TOPICAL VACCINES.|
|Next Article:||IVAX GETS FINAL APPROVAL FOR GENERIC HYPERTENSION TABLETS.|